Ubs Oconnor LLC Dyne Therapeutics, Inc. Transaction History
Ubs Oconnor LLC
- $1.51 Billion
- Q4 2024
A detailed history of Ubs Oconnor LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 20,000 shares of DYN stock, worth $229,000. This represents 0.03% of its overall portfolio holdings.
Number of Shares
20,000Holding current value
$229,000% of portfolio
0.03%Shares
12 transactions
Others Institutions Holding DYN
# of Institutions
212Shares Held
103MCall Options Held
135KPut Options Held
435K-
Atlas Venture Life Science Advisors, LLC8.02MShares$91.8 Million31.16% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$84.6 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.38MShares$84.5 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.7MShares$76.8 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$73.1 Million2.43% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $593M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...